[3] Our updated systematic review found no new evidence that would alter this position. Genetic dyslipidemia conditions (e.g., homozygous familial hypercholesterolemia [HoFH], heterozygous familial hypercholesterolemia [HeFH], TGs >500 mg/dL, etc.) were also excluded from the guideline given their uncommon occurrence and sparse clinical trial data. Although younger patients (i.e., <40 years old) are more common in the DoD, this cohort comprises a low short-term risk population that has been excluded from dyslipidemia intervention trials. Thus, the Work Group was unable to provide evidence-based recommendations for these populations and suggests that providers consider basing treatment decisions for these cohorts on comorbidity, quality of life, and patient s values and preferences. Such shared and informed decision-making should clearly lay out the uncertainty of benefit and known risks associated with pharmacologic treatment. Recommendations The following recommendations were made using a systematic approach considering four domains as per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach as detailed in the section on Methods and Appendix A in the full text Dyslipidemia CPG. These domains include: confidence in the quality of the evidence, balance of desirable and undesirable outcomes (i.e., benefits and harms), patient or provider values and preferences, and other implications, as appropriate (e.g., resource use, equity, acceptability). Topic Sub- topic # Recommendation Strengtha Primary Prevention: Screening and Assessment of Cardiovascular Risk 1. For primary prevention in patients over age 40 and not on statin therapy who have not developed new cardiovascular risk factors (e.g., diabetes, hypertension, tobacco use), we suggest against offering a cardiovascular disease risk assessment more frequently than every five years. Weak against 2. For primary prevention in patients not on statin therapy, we suggest against routinely ordering a lipid panel more frequently than every 10 years. Weak against 3. 